Trial reportAllergy2021
Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics.
Trial report in Allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics.Allergy · 2021Trial
- Roles of Metabolomics in Allergic Rhinitis: From Cell to Bedside Investigations.International journal of molecular sciences · 2026Review
- Metabolomic differences between exanthematous drug eruption and infectious mononucleosis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Focused allergic rhinitis practice parameter for Canada.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- The KAAACI Guidelines for Sublingual Immunotherapy.Allergy, asthma & immunology research · 2024Review
- The early-phase transcriptome and the clinical efficacy analysis in three modes of subcutaneous immunotherapy for allergic rhinitis.The World Allergy Organization journal · 2023Article
- Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-airClinical and translational allergy · 2023Article
- Mechanisms and biomarkers of successful allergen-specific immunotherapy.Asia Pacific allergy · 2022Review
- Article
- COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.Allergy · 2022Article
- Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation.Metabolites · 2022Article
- The Present and Future of Allergen Immunotherapy in Personalized Medicine.Journal of personalized medicine · 2022Review
- Lipid Ligands and Allergenic LTPs: Redefining the Paradigm of the Protein-Centered Vision in Allergy.Frontiers in allergy · 2022Review
- Mast Cell Desensitization in Allergen Immunotherapy.Frontiers in allergy · 2022Review
- Contribution of allergy in the acquisition of uncontrolled severe asthma.Frontiers in medicine · 2022Article
- Biomarkers of AIT: Models of prediction of efficacy.Allergologie select · 2022Review
- Review
- Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous Immunotherapy.Metabolites · 2021Article
- Biomarkers in Hereditary Angioedema.Clinical reviews in allergy & immunology · 2021Review
- Oral Mucosa as a Potential Site for Diagnosis and Treatment of Allergic and Autoimmune Diseases.Foods (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSublingual allergen-specific immunotherapy (SLIT) intervention improves the control of grass pollen allergy by maintaining allergen tolerance after cessation. Despite its widespread use, little is known about systemic effects and kinetics associated to SLIT, as well as the influence of the patient sensitization phenotype (Mono- or Poly-sensitized). In this quest, omics sciences could help to gain new insights to understand SLIT effects.
methods47 grass-pollen-allergic patients were enrolled in a double-blind, placebo-controlled, multicenter trial using GRAZAX® during 2 years. Immunological assays (sIgE, sIgG4, and ISAC) were carried out to 31 patients who finished the trial. Additionally, serum and PBMCs samples were analyzed by metabolomics and transcriptomics, respectively. Based on their sensitization level, 22 patients were allocated in Mono- or Poly-sensitized groups, excluding patients allergic to epithelia. Individuals were compared based on their treatment (Active/Placebo) and sensitization level (Mono/Poly).
resultsKinetics of serological changes agreed with those previously described. At two years of SLIT, there are scarce systemic changes that could be associated to improvement in systemic inflammation. Poly-sensitized patients presented a higher inflammation at inclusion, while Mono-sensitized patients presented a reduced activity of mast cells and phagocytes as an effect of the treatment.
conclusionsThe most relevant systemic change detected after two years of SLIT was the desensitization of effector cells, which was only detected in Mono-sensitized patients. This change may be related to the clinical improvement, as previously reported, and, together with the other results, may explain why clinical effect is lost if SLIT is discontinued at this point.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.